Evaluation of Therapeutic Effect of Contrast-enhanced Ultrasonography in Hepatic Carcinoma Radiofrequency Ablation and Comparison with Conventional Ultrasonography and Enhanced Computed Tomography  by Zheng, Qichao & Wu, Meng
Journal of Medical Ultrasound (2015) 23, 76e81Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jmu-onl ine.comORIGINAL ARTICLEEvaluation of Therapeutic Effect of
Contrast-enhanced Ultrasonography in
Hepatic Carcinoma Radiofrequency Ablation
and Comparison with Conventional
Ultrasonography and Enhanced Computed
Tomography
Qichao Zheng, Meng Wu*Department of Ultrasonography, Zhongnan Hospital of Wuhan University, Wuhan City, Hubei Province
430071, ChinaReceived 4 November 2014; accepted 30 January 2015
Available online 23 March 2015KEYWORDS
contrast agent,
contrast-enhanced
ultrasonography,
hepatic malignant
tumor,
radiofrequency
ablationConflicts of interest: The authors
* Correspondence to: Dr Meng Wu, D
City 430071, Hubei Province, China.
E-mail address: xnjn819@163.com
http://dx.doi.org/10.1016/j.jmu.2015
0929-6441/ª 2015, Elsevier Taiwan LLObjective: This paper aims to discuss the evaluation of the therapeutic effect of contrast-
enhanced ultrasonography (CEUS) in radiofrequency ablation (RFA) for liver cancer and its
application value.
Methods: A total of 80 patients (120 hepatic malignant tumor lesions) were treated using RFA,
and CEUS was conducted on the liver before and after the treatment. Sixty-five patients (85/
120 tumor lesions) had primary hepatic carcinoma and 11 (30/120 tumor lesions) had metasta-
tic hepatic carcinoma (6 cases of 15 lesions had colorectal carcinoma, 3 cases of 8 lesions had
lung carcinoma, and 2 cases of 7 lesions had gastric carcinoma). Four patients (5 lesions) had
recurrence. Prior to the treatment, CEUS accurately guided the RFA of lesions, and after the
treatment, the accuracy of CEUS was compared with conventional ultrasonography and
enhanced computed tomography (CT).
Results: After the RFA, there were two cases of bile leakage, two cases of bleeding, and three
cases of hydrothorax, and 20 cases had fever. In the CEUS performed after the operation, 114
of the 120 lesions (94.6%) were not filled with contrast agent in the arterial phase, venous
phase, and delayed phase, indicating that the tumor lesions were totally inactivated. In the
remaining six lesions, the arterial phase was enhanced partially on the edge, indicating sus-
pected partial residues of tumor lesions. The final diagnosis was based on the aforementioned
two kinds of imaging examinations in combination with the level of tumor markers, needledeclare that they have no conflicts of interest.
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Therapeutic Effect of CEUS in RFA 77biopsy, and follow-up visits of over 1 month. Based on the therapeutic effects on the tumor
after the operation with the final diagnosis as the standards, the accuracy of CEUS was
94.6%, whereas that of contrast-enhanced CT (CECT) and conventional ultrasonography was
93.4% and 60.5%, respectively. A comparative analysis was performed, which indicated that
the difference between CEUS and conventional ultrasonography was of statistical significance
(c2Z 5.42, p < 0.05). A comparison between conventional ultrasonography and CECT was also
of statistical significance (c2 Z 5.14, p < 0.05); however, the comparison between CEUS and
CECT indicated no statistical significance (c2 Z 7.54, p > 0.05).
Conclusion: CEUS has important value of clinical application both prior to and after RFA oper-
ations. Prior to the operation, CEUS can accurately guide the RFA treatment, whereas after the
operation, CEUS is an important method to evaluate the inactivation after the treatment, and
can be an important means for follow-up visits for partial treatment of hepatic carcinoma.
ª 2015, Elsevier Taiwan LLC and the Chinese Taipei Society of Ultrasound in Medicine.
Open access under CC BY-NC-ND license.Introduction
Statistical reports indicate that hepatic carcinoma, one of
the most common malignant tumors, is responsible for the
death of 500,000 people worldwide annually. Themost likely
way to cure hepatic carcinoma is surgical treatment, and the
most common operative procedures are hepatic trans-
plantation and hepatectomy. Because of the shortage of
donators, most patients receive hepatectomy. However,
clinical symptoms in the early stage of hepatic carcinoma are
not obvious when the patient visits a doctor, and hepatec-
tomy is not a suitable option in the later stages of the disease
[1]. In recent years, with the development in medical tech-
nology, radiofrequency, microwave, and transcatheter che-
moembolization are used in those patients who are not able
to receive operative treatments. The problem still exists
though. The tumor may not be inactivated totally or may
recur in a short period, and therefore, minimally invasive
effect is limited. At present, the key problem is how to
improve the curative effect of minimally invasive method to
reduce the recurrence rate of carcinoma.
Because contrast-enhanced ultrasonography (CEUS) and
contrast agent are not matured in terms technology,
contrast-enhanced computed tomography (CECT) and
magnetic resonance imaging (MRI) are usually used to
clinically evaluate the inactivation.
Because of its improvement in examining the sensitive-
ness of tumor blood flow, along with the improvement in
the research and application of new types of contrast
agent, CEUS technology is able to make reliable assess-
ments on the inactivation curative effect of tumor radio-
frequency ablation (RFA). In addition, the technology can
also determine the ablation range and whether the inacti-
vation is thorough [2,3]. Furthermore, as CEUS technology
develops and the technique improves, CEUS can also
determine whether the tumor is benign or malignant in the
early stage for those uncertain nodules. Therefore, pa-
tients can receive RFA earlier, which improves their survival
rate. However, the technology needs further improvement.
Factors such as lack of blood supply to tumors, position of
tumors, fatness and body position of patients, and skills and
experience of doctors will all have an impact on RFA.The paper summarizes the clinical outcome of 80 pa-
tients with hepatic lesion prior to and after the RFA oper-
ation (120 hepatic tumor lesions) admitted to the Zhongnan
Hospital. The therapeutic effects of CEUS were studied and
evaluated, and we also explored the importance of CEUS in
follow-up visits. The results from CEUS were compared with
those from conventional ultrasonography and enhanced CT
examination.
Materials and methods
The study was approved by the Ethical Committee of the
Zhongnan Hospital of Wuhan University, Wu Han City, China
and was performed in accordance with the Declaration of
Helsinki. All treated primary hepatic carcinoma [hepato-
cellular carcinoma (HCC)] and metastatic hepatic carci-
noma (MHC) were confirmed histologically prior to therapy.
All patients enrolled into the study signed an informed
consent prior to participation.
From July 2011 to May 2013, 80 hepatic carcinoma pa-
tients were hospitalized in our hospital, including 65 male
and 15 female patients (age, 40e75 years; average age, of
55.4  4.5 years). Of these, 65 patients had primary hepatic
carcinoma (HCC), and 11 patients had MHC (6 patients with
colorectal cancer, 3 with lung carcinoma, and 2 with gastric
carcinoma), and the remaining four patients had post-
operative recurrence. All 80 patients were determined as
having hepatic carcinoma by ultrasound-guided puncture
biopsy method. Prior to the RFA treatment, CEUS can
examine the size, number, and distribution of tumors. If
tumor lesions are near the intestine and great vessels, or
widely distributed with more than three tumor lesions, the
RFA treatment is generally not suitable. A total of 120 he-
patic carcinoma lesions were chosen for RFA treatment.
Prior to treatment, tumor lesion diameter was 1.0e6.1 cm
(average, 3.8 cm). If the tumor lesion diameter was > 5 cm,
we used multipolar needle; if the liver tumor lesion diam-
eter was < 5 cm, single-polar needle was used. A total of
110 lesions received ultrasound-guided percutaneous
transhepatic RFA with local anesthesia. The remaining 10
lesions received 10 ultrasound-guided RFA with general
anesthesia.
78 Q. Zheng, M. WuFor ultrasound examinations, GEE9 (General Electric E9,
Fairfield City, Connecticut, USA) ultrasonography diagnostic
instrument (probe, C1eC5; frequency, 2.0e5.0 MHz; and
mechanical index, 0.11) and CEUS imaging program were
used. The contrast agent was sulfur hexafluoride [SF6;
SonoVue (Bracco Corporate)] with a mean microbubble
diameter of 2.5 mm of the phospholipid microcyst. The
contrast agent, in the form of lyophilized powder, was
dissolved in 5 mL normal saline. After shaking, the contrast
agent is extracted with 2.4 mL normal saline, and then
rapidly injected into the cubital veins. Then 5 mL normal
saline was used to flush the tube.
CEUS method
The patient lies on the back or in the left lateral position.
The conventional ultrasound examination was performed
prior to CEUS to observe the lesion status, lesion internal
echo, and blood flow situation. The tumor size, number,
and distribution, and its association with the nearby intes-
tinal canal and great vessels were then measured. The CEUS
software was turned on after an initial diagnosis. The whole
process was observed for 6 minutes on a real-time basis to
observe the arterial phase (10e30 seconds), portal phase
(30e120 seconds), and late phase (121e360 seconds).
Then, with the surrounding liver parenchyma as compari-
son, the development of tumor lesions was observed.
Observe the changes in peak time and item start of washout
time. Also, observe if any occurrence of abnormal contrast
agent gathering area in hepatic perfusion; the time and its
position in the liver was recorded if any gathering occurred.
Treatment
Prior to the operation, the conventional examinations of
blood routine, blood coagulation function, and hepatorenal
function were conducted. If the results of all these exami-
nations were normal, the patients were asked not to eat for
8 hours prior to the procedure. Prior to RFA, the patient can
lie either on their back or in the left lateral position. Under
conditions of local or general anesthesia and after local
disinfection, the skin was punctured (depth, 0.5 cm), and
the range, puncture method, and treatment target were
determined according to CEUS results prior to the operation
(Fig. 1A). The United States-made RITA 1500X RF generator
has a generator frequency of 460 kHz and the main engine
delivers 150 W of power, and this was used in the operation.
Guided by ultrasound, a 14-G insulation electrode was
inserted into the tumor. High-frequency current flows
through the umbrella-shaped electrode to the tumor tissue.
Because of friction and shock, the temperature reaches as
high as 100C to form a heat coagulation lesion, whose size
varied between 2.0 cm and 5.0 cm. In this way, the tumor
tissue will be inactivated [4]. The procedure takes
approximately 20 minutes to ablate a ball-shaped lesion
with a diameter of 5 cm; however, more time is required to
ablate a bigger tumor with more lesions. After RFA starts,
the whole process of tumor ablation is monitored by ultra-
sound continuously, so as to see the well-distributed strong
echo in the tumor lesion area. After the RFA operation,
conventional CEUS should be conducted to verify the result(Fig. 1B) [5]. If a tumor lesion is near the right liver with its
upper region < 1 cm of the diaphragm, the patient lies on
the left side to show the tumor outline with CEUS. The
needle is then punctured in for RFA in order to increase its
accuracy. Upon the completion of the RFA, the conventional
ultrasonography is first conducted to observe the boundary,
size, echo, and blood supply of lesions after RFA to initially
evaluate the therapeutic effects of RFA. The CEUS exami-
nation is conducted to observe whether there are abnormal
contrast gathering areas inside or around the lesions in the
arterial or portal phase, and whether there is prior clear-
ance in the late period. No filling of contrast agent in the
phase indicates full inactivation of the tumor (Fig. 1B).
Gathering of contrast agent in or around the tumor in the
arterial phase or in the late phase indicates the residual or
recurrence of tumors. CEUS examination is conducted 1
month after the RFA operation to compare the results with
the prior examination to determine whether the lesions are
fully inactivated or remain (Figs. 2A and 3A).
Spiral CT (Siemens) examination was contemporarily
conducted for all the 80 patients (120 lesions) by axial view
plain scanning and enhancement plain scanning. The axial
view plain scanning was performed with a thickness of
5 mm and obtains the axial view plain image. Enhancement
plain scanning was also performed with a thickness of
5 mm, with the injection of iohexol contrast agent bolus
into the elbow vein (1.5e2.0 mL/kg, 80e100 mL) to obtain
axial scanning images of the arterial phase (25e35 seconds)
and portal vein phase (50e55 seconds). Then a three-
dimensional diagram of the coronal region is obtained, to
observe the inner part and edge of the focus in the arterial
and portal vein phases after ablation. Enhancement in the
inner part or edge indicates residual and recurrence of
tumor (Fig. 2B and C); if after ablation, there is no obvious
enhancement in the arterial phase and the portal vein
phase, then the tumor is inactivated (Fig. 3B and C). For
conventional ultrasonography, CEUS and CT, blinding is
adopted, so the diagnosis can be compared with the final
diagnosis.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0
(SPSS, Statistical Product and Service Solutions Inc, Chicago,
Illinois, USA). Two kinds of samples (CEUS and CDFI, CEUS
and CECT, CECT and CDFI) are compared for measurement
material and the constituent ratio is compared by c2 test. A
p value < 0.05 was taken to be significant.
Results
Of the 80 patients (120 lesions) having completed RFA beside
the bed or in the operation theater, a few patients suffered
from complications related to the operation: two patients
had bile leakage, two had bleeding, and three had hydro-
thorax. A total of 20 patients suffered from malignant
emesis, fever, and ache in the hepatic area to different de-
grees, which alleviated within 1 week following treatment.
After RFA, the final diagnosis of inactivation or residual
or recurrence of tumors was based on more than two
radiographic examinations (CEUS/MRI/CT) in combination
Fig. 1 (A) Prior to hepatic radiofrequency ablation (RFA), the image of the tumor lesions from conventional ultrasonography is
not clear, whereas that of the tumor lesions from contrast-enhanced ultrasonography (CEUS) is clear. (B) After RFA for the hepatic
tumor lesion, CEUS shows no obvious filling in of the contrast agent in the low-echo tumor lesion. In addition, it appears that the
tumor is completely inactivated.
Fig. 2 (AeC) Contrast-enhanced ultrasonography/computed tomography images. Status of hepatic tumor lesion 1 month after
the radiofrequency ablation (after the injection of a contrast agent). There is rapid enhancement in the edge of tumor lesion in the
arterial and portal vein phases. There is continuous low enhancement in the late phase, which indicates recurrence.
Therapeutic Effect of CEUS in RFA 79with the level of tumor markers, needle biopsy, and follow-
up visits of over 1 month. If the results of more than two
radiographic examination results are negative, the level of
tumor marker reduces to normal, and there is no obvious
change after 1 month of follow-up visit, then inactivation of
tumor is indicated (Fig. 3AeC). However, when the lesionFig. 3 (AeC) Contrast-enhanced ultrasonography/computed tom
after the radiofrequency ablation. There is no obvious filling in of
which indicates that the tumor lesion was completely inactivated.amplifies with echo nodules around, CEUS and CT results
show enhancement or recession, the level of tumor marker
rises or is normal with positive result of needle biopsy, the
recurrence or residual of the tumor is indicated
(Fig. 2AeC). After 1 month, conventional ultrasonography,
CEUS, and CECT examinations were conducted: ultrasoundography images. The status of hepatic tumor lesion 1 month
contrast agent in the tumor lesion. There is a low-echo area,
Table 1 Comparison of results of CEUS, CECT, and CDFI in 80 patients (120 lesions) after RFA.
Comparison group Method Full
inactivation no.
Partial inactivation þ suspected
residual io.
c2 p Examination result
CEUS and CDFI CEUS 114 6 5.14 0.035 **
CDFI 72 48
CEUS and CECT CEUS 114 6 7.54 0.074 e
CECT 112 8
CECT and CDFI CECT 112 8 5.42 0.038 **
CDFI 72 48
“d” indicates difference with no statistical significance.
p < 0.05 indicates statistical significance.
“**” indicates difference with statistical significance.
CDFI Z color Doppler flow imaging; CECT Z contrast-enhanced computed tomography; CEUS Z contrast-enhanced ultrasonography;
RFA Z radiofrequency ablation.
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inactivated, 10 lesions were partially inactivated (Fig. 2A),
and 48 lesions were suspected to be lesions remaining after
RFA treatment. The accuracy of detection in this case was
60.5%. According to CEUS examination results, 110 lesions
were fully inactivated (Fig. 3A), four lesions were partially
inactivated, and six lesions were suspected to be remaining
after RFA treatment. The accuracy of this method was
94.6% (Fig. 2A). The CECT examination results showed that
110 lesions were fully inactivated (Fig. 3B and C), two le-
sions were partially inactivated, and eight lesions were
suspected to be remaining after RFA treatment. The ac-
curacy in this method was 93.4% (Fig. 2B and C). There was
a difference between the statistical analysis for accuracy of
conventional ultrasound and CEUS examination results
(c2 Z 5.14, p < 0.05), as well as between statistical
analysis for accuracy of conventional ultrasound and CECT
examination results (c2 Z 5.42, p < 0.05). The statistical
analysis for accuracy of CEUS and CECT examination results
was of no statistical significance (c2 Z 7.54, p > 0.05;
Table 1).Discussion
Rossi reported the application of RFA in liver tumor as early
as in 1995 [6]. Until now, RFA is one of the most commonly
used and important methods for partial physical ablation
treatment of liver tumors. Given the developments in
technology and constant improvement of clinical thera-
peutic effects, RFA plays an increasingly important role.
Imaging methods also play an important role in the
assessment and follow-up visits for hepatic carcinoma.
Conventional ultrasonography is a common method for
follow-up visits after treatment to evaluate the level of
inactivation of the tumor through the boundary, size,
changes of lesions, and the status of blood supplies in the
lesion. Some studies have noted that the conventional ul-
trasonography is limited in judging the therapeutic effects
[7]. Color Doppler ultrasonography or even power Doppler
ultrasonography has limitations in detection of capillaries,
and is thus unable to fully reflect the extent of necrosis and
survival of tumor after RFA treatment. The recurrence rate
of hepatic carcinoma after RFA treatment is high [8]. Along
with the application of the third-generation contrast agent(SonoVue), ultrasonography is increasingly applied for
detecting hepatic-space-occupying lesion. Especially,
increasing attention is paid to the application of RFA in
hepatic malignancy ablation. Furthermore, the develop-
ment of CEUS technology has taken medical ultrasonogra-
phy to a new level of diagnosing and treating diseases of the
microcirculatory system [9]. Contrast agent will not diffuse
into the intercellular space with blood. In addition, they
are able to more accurately reflect blood supply in the
tumor and it is also possible to observe the whole instilla-
tion procedure. The tumor lesion can be compared more
clearly than prior to the ultrasound contrast treatment.
Tumor location, size, and microscopic extension will thus
be determined more accurately, and the route and position
of needles will be more accurately guided to formulate a
more precise therapy plan, enabling effective RFA treat-
ment. At present, the basis to evaluate the therapeutic
effect of RFA and the possibility of recurrence is mainly
enhanced CT and MRI. Some scholars consider enhanced CT
as the golden standard for evaluating the therapeutic ef-
fects of RFA treatment [10]. In the follow-up visits after
RFA, two metastases were found to be false negative. This
could be explained as follows: CT showed no obvious
enhancement in the arterial phase, indicating inactivation
of the tumor. However, CEUS indicated ring enhancements
around the lesions in the arterial phase and slight recession
in the portal phase, which was eventually diagnosed as
tumor recurrence. This was confirmed by 1-month follow-
up visits and needle biopsy.
In addition, enhanced CT is not applied for immediate
evaluation after RFA, and is usually conducted only 1 month
later [11]. Therefore, we applied ultrasonography prior to
and after the RFA, which may not only improve the
detection rate of tumors, but can also better guide needle
direction, needle pitch, depth, and single-polar or multi-
polar needles for RFA, and evaluate the full inactivation
and residual of tumors after RFA. Compared with color
Doppler flow imaging, CEUS can surmount the effects of
depth and blood of tumors, and can more accurately reflect
the position and size of the tumors. The technique is ad-
vantageous to determine the ablation scope of RFA and
clinical therapeutic effects and the extent of tumor inac-
tivation after RFA. Compared with enhanced CT, CEUS has
real-time monitoring and more practical and clinical
application values. In addition, it has the advantages of
Therapeutic Effect of CEUS in RFA 81easy and real-time dynamic observation in terms of making
a judgment on tumor inactivation (94.6%) as compared with
CT (93.4%). However, with regard to CEUS, there are still
difficulties in display, real-time monitoring, and evaluation
of tumor inactivation in those with a lack of blood supplies.
However, along with the development of scientific and ul-
trasonography technology, and with the availability of ul-
trasonography instruments with high sensitivities and new
types of contrast agent, ultrasonography can sensitively
judge the inactivation or survival of tumor after RFA
treatment with no obvious difference with CT in terms of
diagnosis results. It can be an effective method to evaluate
the therapeutic effect of RFA treatment and an important
method for follow-up visits of partial treatment with high
clinical application value.
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